LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM) today announced that the Mayo Clinic Proceedings medical journal published in their October installment, an open-label study by Dr. Harold C. Urschel, III, M.D., M.M.A. of the pharmacological component of the PROMETA® Treatment Program for methamphetamine dependence. The study found that this component of the PROMETA® Treatment Program persistently reduced methamphetamine cravings and use. The Mayo Clinic Proceedings journal is a peer-reviewed publication of the prestigious Mayo Clinic in Rochester, Minnesota.
